We can readily understand why investors are attracted to unprofitable companies. For example, Prescient Therapeutics (ASX:PTX) shareholders have done very well over the last year, with the…

Two ASX-listed ventures are among the companies now investing billions of dollars to develop an emerging immunotherapy treatment known as CAR-T. From the upcoming Innovation…

The burgeoning CAR T therapy industry has passed another significant milestone after the US Food and Drug Administration (FDA) approved Breyanzi for use in certain…

Australian listed biotech company Prescient Therapeutics (ASX: PTX) is forging a path for other prospective cancer treatments, by developing a platform to improve the performance…

StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this edition, host Dr Nigel Finch discusses cancer…

Several major pharmaceutical companies have cautioned they’re unable to widely use revolutionary CAR-T cancer treatments, until an “off-the-shelf product” becomes available – highlighting the need…

There are several ASX stocks fighting cancer but only a few are addressing blood cancers. The Leukaemia Foundation has released figures showing that blood cancers…

Are you looking to add some exposure to the small side of the market to your portfolio? Then you might want to get better acquainted…

Prescient Therapeutics (PTX) outperformed its health sector peers on the ASX today after releasing its quarterly report for the three months to December 31. In…

Melbourne-based Prescient will focus development of its OmniCAR platform into three programs: the blood cancer acute myeloid leukemia (AML); solid tumours including breast, ovarian and…